Highlights

  • Syntara is investigating therapies that target extracellular matrix dysfunction and inflammatory processes.
  • The FDA supported the proposed Phase 2b study design for amsulostat in myelofibrosis in April 2026.
  • The company announced an A$8.0 million institutional placement in April 2026, before costs.
  • An October 2026 update addressed recruitment in a Phase 1b study of topical SNT-9465 for skin scarring.
  • SNT-4728 Phase 2 findings reported in July and October 2026 concerned brain inflammation and motor assessments.

Syntara Limited (ASX:SNT) is a clinical-stage drug developer working on treatments for blood cancers and conditions involving inflammation and fibrosis. Its research includes compounds that inhibit lysyl oxidase enzymes, which are involved in the formation and remodelling of connective tissue. During 2026, the company reported developments across its amsulostat, SNT-9465 and SNT-4728 programs, alongside an equity financing initiative.

Amsulostat and the Myelofibrosis Program

Amsulostat is Syntara’s lead investigational medicine for myelofibrosis, a blood cancer involving abnormal scarring within bone marrow. The compound targets the lysyl oxidase family of enzymes. This mechanism is relevant to research into fibrosis, but clinical benefit must be established through controlled studies rather than inferred from enzyme activity alone.

On 28 April 2026, Syntara Limited (ASX:SNT) announced that feedback from a Type C meeting with the US Food and Drug Administration supported the design of a proposed placebo-controlled Phase 2b study in approximately 100 patients. The announcement concerned study planning and regulatory interaction; it did not represent marketing approval or confirmation of effectiveness.

Further Research in Scarring and Neuroinflammation

The company also continued developing SNT-9465, a topical pan-lysyl oxidase inhibitor intended for research into skin scarring. In an update dated 1 October 2026, Syntara Limited (ASX:SNT) said recruitment in its Phase 1b study involving hypertrophic sternotomy scars was approaching completion for the initial 20-participant cohort and described an expansion of the study. The program remains investigational, with tolerability and clinical outcomes requiring further assessment.

SNT-4728, another research candidate, was examined in a randomised, double-blind, placebo-controlled Phase 2 study involving isolated REM sleep behaviour disorder. On 6 July 2026, Syntara Limited (ASX:SNT) reported preliminary evidence of reduced brain inflammation in a particular region, while an additional 7 October announcement discussed clinician-assessed motor signs. These findings relate to exploratory measures and should not be interpreted as proof that the treatment prevents Parkinson’s disease.

2026 Funding and Development Considerations

On 29 April 2026, Syntara announced commitments for an A$8.0 million two-tranche institutional placement before costs and plans for a non-underwritten share purchase plan of approximately A$2.0 million. Separately, the company reported receiving approximately A$1.7 million (£900,000) in March 2026 upon the achievement of a development milestone in the SNT-4728 study. The disclosures illustrate the importance of financing and external program support in maintaining a multi-asset clinical pipeline.

For Syntara Limited (ASX:SNT), material uncertainties include whether clinical outcomes can be replicated in larger trials, whether regulators accept future submissions, and the expenditure required to complete development. Early biological signals, regulatory feedback on study design and recruitment progress are distinct from final evidence of safety and efficacy.

Key Insights

Syntara Limited (ASX:SNT) entered the latter part of 2026 with activity across bone marrow fibrosis, topical scarring and neuroinflammation research. The updates establish the status of several investigational programs rather than commercial treatment outcomes. Later clinical readouts, trial design decisions and funding disclosures will determine how these projects progress through development.